Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design) & 10y following bios. Preplanned pause.

Lyon, France
Joined April 2015
Dear Friends, The Breakthrough Bike Challenge was founded to raise funds supporting breakthroughs in cancer research at Penn Medicine's Abramson Cancer Center. Please consider making a tax deductible donation fueling the research that will deliver breakthroughs at my page here runsignup.com/Race/175770/Do… Why will I ride? To honor the patients who have volunteered for our cancer immunotherapy clinical trials who have invested their faith and hope in our development of new medicines. To honor those living with cancer and those free from cancer. To honor the memories of my Uncle Arthur and my Aunt Glenda. To honor the memories of dear friends Richard and Laurie Carroll. To honor friend and coworker Andrea Brennan. Andrea carried with her words spoken by Stuart Scott at the ESPYs: "When you die, it does not mean that you lose to cancer. You beat cancer by how you live, why you live, and in the manner in which you live. I know that I can make an impactful contribution to conquering this disease. Please support me and create hope for cancer patients by making a donation today. Our team CARs Pedaling for Cures includes members and friends of the Center for Cellular Immunotherapies (CCI) where we are focused on the development of personalized cell and gene based therapies. The CCI team has brought to patients many first in human clinical trials. With the explosion of new results in cancer immunotherapy and chimeric antigen receptor T cells, what was once thought quixotic, is now viewed with excitement and enthusiasm. We celebrate and thank patients who have enrolled in our immunotherapy trials. Without their dedication and placing their faith and hope in us, we would not be able to make progress in the development of new medicines. In 2022, we celebrated the release of the documentary film Of Medicine and Miracles, which premiered at the Tribeca Film Festival and tells an interwoven story of leukemia survivor Emily Whitehead and Dr. Carl June’s experiences in the development of CAR T cell immunotherapy therapy. The film has been released on several streaming services that I’ve pasted at bottom. Last year, a song honoring CAR T cell patients that I co-wrote was commercially released, with a music video you can find at RingThatBellSong.com Thank you for your support, follow me on Twitter (X) @BLLPHD and I will keep you posted on my progress! Bruce Of Medicine and Miracles Trailer: youtu.be/ee1fcEEbrH8?feature… And the streaming links Apple tv.apple.com/us/movie/of-med… Amazon amazon.com/gp/video/detail/B… Google Play play.google.com/store/movies… Vimeo On Demand vimeo.com/ondemand/ofmedicin…
🤖 Made with AI
1
2
1,330
Bertrand Delsuc retweeted
Useful slide to explain clinical outcomes for pts with 1st line, 2nd line and Beyond For HR+ /Her2 -ve MBC . Money 💰 slide by @jhaveri_komal @asco #asco25 @OncoAlert @OncBrothers
7
57
1
207
28,799
Bertrand Delsuc retweeted
From the same #ASCO25 talk: biparatopic ADCs and bispecific ADCs
2
4
15
5,756
Bertrand Delsuc retweeted
Catching up on some #ASCO25 sessions, I came across this on dual-payload ADCs from Patricia LoRusso's clinical science symposium
3
10
1
23
7,037
💫 Immunology 🔬 TDLN ⭐️ The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy. #immunity #tdKN
1
2
3
2,397
Truth Social has crashed from the traffic surge and in so doing accidentally created a hauntingly poignant image.
657
24,724
956
233,241
5,306,277
Bertrand Delsuc retweeted
“Ring That Bell” is the #1 song on the Amazon music country chart! @BLLPHD @PennMedicine @PennCancer #immunotherapy #cancer 🎻❤️🎻
1
3
9
2,026
Bertrand Delsuc retweeted
new CBER director Vinay Prasad slide at NORD conference this morning on the future of rare disease drugs
8
26
9
113
45,012
Bertrand Delsuc retweeted
This is Evopoint's Claudin18.2 ADC licensed by $ALPMF on Friday. #ASCO25 poster cites Claudin18.2 expression down to 5%, but author wouldn't divulge more detailed splits
4
2
6
4,307
Bertrand Delsuc retweeted
Circadian rhythms with potentially major impact on T cell circulation and exhaustion. Do we need to control for time of infusion in studies? Should we go back and look at results of prior studies by time of infusion? Congratulations to @zhang_yongchang and team!
4
33
6
178
21,600
A practice changing trial that IMMEDIATELY needs to be challenged. 2L TDXd only 10%, adj SOC was less than usual, and given PATINA 44mos, a stop-TDXd switch to CDK4/5 + H(P) needs to be explored for QOL. We should not minimize the 48% Fatigue, incld ~8% G3 #ASCO25 @OncoAlert
7
47
1
114
10,645
Bertrand Delsuc retweeted
ABBV-400 a new antiMET ADC tested in pretreated EGFRm NSCLC reported ORR 26% and DoR 9.8 regardless cMET expression. It is a crowded space with BL-B01D1, DB-1310, dual TKI EGFR/ET etc. Can we ⬆️ ABBV-400 combining with osimertinib?TelisoV + Osi > Teliso alone in mEGFR 🫁#ASCO25
1
28
1
71
8,210
Bertrand Delsuc retweeted
In a randomized trial (n=210), early time-of-day (ToD) ICI + chemo (before 3 PM) led to: - mPFS: 11.3 vs 5.7 mo (HR 0.42) - mOS: NR vs 16.4 mo (HR 0.45) Very intriguing data-suggests a potential role for circadian biology in ICI efficacy? #ASCO25
5
18
2,764
Bertrand Delsuc retweeted
SAVANNAH (osi-savo P2, MET FISH/IHC+) CNS subset N=73 randomised: 56% xover ORR 58% 16%: DOR 11.8 vs 4.5mo PFS 8.3 vs 3.6mo; IcORR 43% (combo) Confirms need for dual inhibition of targets and systemic + intracranial efficacy. Await SAFFRON Ready for MET IHC? #ASCO25
9
1
14
3,312
Bertrand Delsuc retweeted
Here's Huabo's sotiburafusp alfa (HB0025), a PD-L1 x VEGF trap fusion protein. 84% ORR in endometrial cancer, and it might cost you less than $1.25bn #ASCO25 $BNTX $SMMT $PFE
25
15
4
86
39,099
Bertrand Delsuc retweeted
$NVS Pluvicto positive rPFS in PSMA +ve mHSPC at interim. +ve trend in OS and based on feedback from FDA filing for review in 2H25 novartis.com/news/media-rele…
1
1
10
3,439
Bertrand Delsuc retweeted
🔎Role of DB-1311/BNT324 (novel B7H3 ADC) in CRPC patients who are heavily pretreated? ✅Agent showed efficacy; among 52 pts: ORR seen in 42.3%, DCR 90.4%, 6m rPFS 67.7% ✅Outcomes appeared better in earlier treatment lines Currently enrolling post Lu-177 CRPC and taxane naive CRPC for more answers! @ASCO @oncoalert @Oncolive @TargetedOnc @OncoReporte @Urotoday #ASCO25 #genitourinarycancer @WinshipAtEmory
1
2
13
2,133